Mounjaro Patient Information PDF: What the Official Leaflet Covers

What the MHRA-approved PIL is based on, and why that matters

Every PIL published on the eMC is derived from the Summary of Product Characteristics (SmPC), which is the technical document submitted to and approved by the MHRA when a medicine receives its UK licence. The Mounjaro SmPC runs to dozens of pages; the PIL distils the clinically essential parts into language accessible to patients. Eli Lilly must update both documents whenever new safety information emerges or the licence is amended, so the eMC version is always the current one. Printed leaflets inside older pen boxes may lag behind a digital update, which is one reason the background on Mounjaro's UK licence is worth reading alongside the official document.

Tirzepatide received its UK weight-management licence as a Black Triangle (▼) medicine, meaning it is subject to additional MHRA monitoring. The PIL reflects that status by including a prompt to report suspected side effects via the Yellow Card scheme at yellowcard.mhra.gov.uk. That reporting channel feeds directly into the post-market surveillance that keeps the document current, so patient reports genuinely shape future PIL revisions.

The NHS tirzepatide medicines page also summarises many of the key PIL facts in plain English, a useful companion read, though the eMC document remains the formal UK reference.

Dose schedule, strengths and storage: the specifics the PDF sets out

A question our prescribers hear most weeks is whether 2.5 mg is strong enough to do anything. The PIL addresses this directly: that starting strength exists so your body can adjust to the medicine before the therapeutic doses begin. Treatment then progresses through 5, 7.5, 10, 12.5 and 15 mg in steps timed by the prescriber, typically around four weeks at each level. The leaflet is explicit that patients should not change their own dose, that decision belongs to the clinician reviewing their progress. For more on how the titration schedule works in practice, you can read the tirzepatide information sheet, which sets out the clinical context.

Storage is covered in a dedicated section of the PIL. Mounjaro pens must be refrigerated at 2–8°C; there is a limited window during which they can be kept at room temperature, but the exact duration is stated in the leaflet itself and you should refer to that figure rather than relying on any third-party summary. The PIL also covers what to do if a pen has been frozen or exposed to direct sunlight, and how to dispose of used pens safely.

Each KwikPen contains four doses, one per week for a full four-week supply. The leaflet walks through the injection technique step by step, covering site rotation across the abdomen, thigh and upper arm, and the importance of changing the injection site each week.

Side effects section: what the PIL lists and how to read it

The side-effect tables in the Mounjaro patient information document are arranged by frequency band: very common (affecting more than 1 in 10 people), common, uncommon and rare. Gastrointestinal effects sit in the very common category, nausea, diarrhoea, vomiting, constipation and indigestion appear most often during dose increases and tend to settle within the first week or two at a new level. The NHS tirzepatide page covers the most frequently reported effects in plain English and is worth reading alongside the PIL.

The PIL also flags signs that require urgent medical attention. Severe, persistent stomach pain that radiates to the back (with or without vomiting) should be assessed by a doctor promptly, as it can indicate pancreatitis, a known but uncommon risk with GLP-1 medicines. The MHRA highlighted this in a Drug Safety Update in January 2026. Gallbladder symptoms, signs of a serious allergic reaction and symptoms of dehydration following severe vomiting or diarrhoea are also listed as reasons to seek medical help without delay.

The PIL's contraindications section names conditions that rule out use entirely, a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 is among them. Pregnancy, breastfeeding and active attempts to conceive are also listed: Mounjaro is not recommended in any of these situations, and the leaflet advises using effective contraception during treatment. Women taking oral contraceptives should note the PIL's guidance on the interaction between tirzepatide and pill absorption, covered in more detail on the Mounjaro patient info page.

How the tirzepatide patient information fits into your treatment at a registered pharmacy

UK law requires that patients are given access to the PIL before or at the point of dispensing. At a GPhC-registered online pharmacy like nume (GPhC premises number 9012878, verifiable at pharmacyregulation.org), the PIL arrives with your pen and the prescriber's review covers the sections most relevant to your health history. That is a clinical consultation, not an automated process.

The PIL does not substitute for that review. It cannot account for your specific comorbidities, other medicines you take, or your current dose history. That is why the document itself directs readers back to their prescriber or pharmacist repeatedly, particularly for missed doses, switching scenarios and any decision to change the dose. If you want to read the full Mounjaro patient information leaflet before your consultation, that page sets out everything the official document contains so you can prepare any questions in advance. If you are thinking about what Mounjaro treatment costs as a private patient, the Mounjaro pricing page explains what a legitimate private prescription includes.

The PIL is also the right place to check before travel, storage questions arise or you experience something unexpected. Keep the printed leaflet from your first pen; subsequent boxes may carry updated versions if the licence has been amended. If you have questions the document raises but does not fully answer for your situation, you may find it helpful to read through the Mounjaro information leaflet we have put together, which explains the key sections in plain English alongside the clinical team's commentary. You can speak to our prescribers through a free consultation at any point before or during treatment.